Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.40 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21050994 | 0.84 | ALDH1A1 (0.43) | ALDH1A1HTTMAPTL3MBTL1DAO | |
| SCHEMBL2741641 | 0.82 | KDM4E (0.42) | ALDH1A1HTTMAPT | |
| SCHEMBL21902913 | 0.81 | GABRA1 (0.41) | ALDH1A1HTTMAPTL3MBTL1DPP4 | |
| SCHEMBL16047309 | 0.80 | STAT3 (0.49) | ALDH1A1HTTMAPTL3MBTL1 | |
| SCHEMBL16105820 | 0.79 | DAO (0.55) | ALDH1A1HTTDAOTRPV3MAOA | |
| SCHEMBL3571123 | 0.79 | STAT3 (0.43) | ALDH1A1HTTMAPTL3MBTL1DAO | |
| SCHEMBL22242870 | 0.78 | DAO (0.33) | ALDH1A1HTTMAPTL3MBTL1DAO | |
| SCHEMBL2623873 | 0.78 | GABRA1 (0.48) | ALDH1A1HTTMAPTDPP4 | |
| SCHEMBL9176216 | 0.78 | GABRA1 (0.48) | ALDH1A1HTTMAPTDPP4 | |
| SCHEMBL11963166 | 0.78 | TRPV4 (0.49) | DAOMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-11225480-B2 | Malic enzyme inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-01-18 | — | — | US | disclosed |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2021-04-22 | — | — | US | disclosed |
| US-20200231596-A1 | MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE | CANGET BIOTEKPHARMA | 2020-07-23 | — | — | US | disclosed |
| US-9902754-B2 | Modified peptides as potent inhibitors of the PSD-95/NMDA receptor interaction | UNIVERSITY OF COPENHAGEN (DK) | 2018-02-27 | — | — | US | disclosed |
| US-20160176924-A1 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | UNIVERSITY OF COPENHAGEN (DK) | 2016-06-23 | — | — | US | disclosed |
| US-9241967-B2 | Modified peptides as potent inhibitors of the PSD-95/NMDA receptor interaction | UNIVERSITY OF COPENHAGEN (DK) | 2016-01-26 | — | — | US | disclosed |
| US-20110178022-A1 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | UNIVERSITY OF COPENHAGEN (DK) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | ALDH1A1 569/4885HTT 2300/4885MAPT 3935/4885 |
| US-20200231596-A1 | MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE | TP53, BRCA1, MET | ALDH1A1 4214/4885HTT 1090/4885MAPT 1334/4885 |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | ALDH1A1 144/4885HTT 4475/4885MAPT 2817/4885 |
| US-20160176924-A1 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | PSD, GRIN1, GRIN3B | ALDH1A1 4849/4885HTT 2044/4885MAPT 2420/4885 |
| US-20110178022-A1 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | GRIN1, PSD, GRIN3B | ALDH1A1 4851/4885HTT 2224/4885MAPT 2438/4885 |
| US-11225480-B2 | Malic enzyme inhibitors | ME1, RNASE1, ME2 | ALDH1A1 89/4885HTT 4764/4885MAPT 3825/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | ALDH1A1 569/4885HTT 2300/4885MAPT 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.